ALLR

Announcements

Nothing here yet

Daily updates

• Allarity Therapeutics reported new patent and laboratory progress for its stenoparib DRP patient-selection platform, including new IP and CLIA-certified internal testing. Prior Phase 2 ovarian cancer data associated higher stenoparib-DRP scores with improved overall survival, supporting use of the assay for pivotal-trial enrollment and potential partnerships.Oct 1, 2026

FDA designations

• Allarity Therapeutics Receives FDA Fast Track Designation for Stenoparib in Advanced Ovarian CancerAug 26, 2025

News

• Allarity Therapeutics received a Japanese patent for the Stenoparib DRP companion diagnostic, further strengthening Stenoparib developmentSep 15, 2026
• Allarity Therapeutics received CLIA certification, supporting FDA registration of its DRP testing platformJul 8, 2026
• Allarity Therapeutics received a key U.S. patent for its Stenoparib DRP companion diagnosticJul 1, 2026
• Allarity Therapeutics advanced stenoparib toward pivotal development with a Phase 3 manufacturing campaignMay 5, 2026
• Allarity Therapeutics received a notice of allowance from the USPTO for the Stenoparib DRP testApr 27, 2026